Biomerica Studies Fiscal 2021 2nd Quarter Economic Effects and Gives Business enterprise Update

• Biomerica expects completion of enrollment of its Irritable Bowel Syndrome Diagnostic-Guided Therapy scientific demo by finish of April, 2021
   
• Fda actively reviewing Company’s EUA submission for its 1st of its kind “at-home” Blood Collection package made use of with the Biomerica COVID-19 IgG ELISA Lab Check procedure
   
• Easy to use 15-moment COVID-19 Antigen Fast Check, which now has CE Mark, gets initial massive orders

IRVINE, Calif., Jan. 15, 2021 (Globe NEWSWIRE) — Biomerica, Inc. (Nasdaq: BMRA), a world-wide supplier of state-of-the-art healthcare goods, currently introduced economical effects for its 2nd quarter of fiscal 12 months 2021, which finished November 30, 2020.

The Organization described next quarter all over the world income of $1.373 million as as opposed to $1.596 million for the exact same time period in the past yr. The lessen in profits through the quarter was primarily because of lower gross sales in Asia. Nevertheless, revenue in Asia have significantly improved in the very first 50 % of the 3rd fiscal quarter. Web reduction was $1.485 million for the next fiscal quarter in contrast to a net reduction of $.485 million for the very same period in the earlier fiscal 12 months. The boost in web reduction was primarily due to better research and development expenditure, mostly similar to the development of many COVID-19 checks, and better general and administrative charges, mostly due to increases in authorized fees, reserves and personnel/consulting costs. Money and income equivalents were being $5.684 million, and existing assets have been $11.947 million, at the stop of the next fiscal quarter.

The Enterprise announced that the U.S. Foods and Drug Administration (“FDA”) is now actively examining the Company’s Unexpected emergency Use Authorization (“EUA”) application for its COVID-19 IgG ELISA Check along with the Company’s qualified use and at-dwelling Entire Blood Assortment Card procedure. If EUA clearance is granted, it would be the initially for an in-home blood sample assortment method combined with an ELISA take a look at package. This selection process provides the simplicity of a finger-prick blood sample which can be effortlessly collected in many configurations such as houses, colleges, workplace, community care and health care options, and have these samples sent back to a lab to be run on the Company’s really precise ELISA exam. In scientific reports, the finger-prick blood collected samples demonstrated 100% specificity for detecting IgG antibodies to the spike protein of SARS-CoV-2 and % cross-reactivity with quite a few frequent diseases. The Company’s COVID-19 IgG ELISA test makes use of modified trimeric spike protein from the SARS-CoV-2 virus, which is recognized to be the concentrate on of neutralizing antibodies that stop the virus from moving into cells.1

The Business also lately announced that it has gained a CE mark for its new antigen fast examination. The Business has presently been given its initially large European orders and programs to ship the initially component of these orders in the coming weeks. The Organization will now begin promoting this product broadly in Europe and other locations outside of the U.S. Biomerica’s new COVID-19 Antigen Fast Exam is highly moveable, cost-effective and gives outcomes in about 15 minutes with no equipment required to perform or study the take a look at. This test can be executed by health professionals, nurses, school nurses, professional medical assistants, and experienced health care professionals. In unbiased testing at clinics in 3 unique international locations exterior of the U.S., the Biomerica COVID-19 Immediate Antigen Exam demonstrated an over-all overall performance of 94.7% constructive settlement (sensitivity) and 99.7% destructive agreement (specificity) as when compared to lab-primarily based molecular PCR tests. A easy nasal swab is made use of to gather specimens from men and women suspected of getting an lively infection. Affected person samples really should be tested quickly and must not be diluted or employed with viral transport media or frozen specimens.

Also, as formerly introduced, the Enterprise is nearing completion of individual enrollment in the endpoint clinical demo for its InFoods® Irritable Bowel Syndrome (“IBS”) diagnostic-guided treatment (“DGT”). This double-blinded, randomized, controlled clinical trial is validating the Biomerica InFoods® IBS test to take care of the debilitating soreness and struggling of individuals identified with IBS. Employing an antibody guided blood check, the InFoods® IBS merchandise identifies client-precise foodstuff that may ease IBS indications when eliminated from the patient’s diet. Mayo Clinic, Beth Israel Deaconess Health care Centre, Inc., a Harvard Healthcare Faculty Instructing Healthcare facility, Houston Methodist, University of Texas Health Science Center at Houston, and the University of Michigan are collaborating in this research. Biomerica expects to complete affected individual enrollment at these facilities by the conclusion of April, 2021, and to have summary examination final results from the scientific trial by the conclude of July, 2021.

“We have worked to differentiate our COVID-19 products from the levels of competition by concentrating on proprietary approaches of sample collection. For instance, by employing our simple finger-prick blood selection product we can permit a simple collection of a blood sample nearly anywhere (at home, at the business office, or virtually any other locale). At the identical time, we are now launching our place of care 15-moment antigen take a look at. Most importantly, we are pretty excited about nearing completion of individual enrollment in our endpoint scientific demo for its InFoods® IBS diagnostic-guided treatment. While we are proud to be serving to with the recent world wide pandemic, it is essential to notice that our major long-expression concentration proceeds to be on validation and commercialization of products based on our patented InFoods® technological innovation system. We continue on to consider our InFoods products could revolutionize the way folks are diagnosed and handled for a variety of gastrointestinal conditions, though offering Biomerica sizable earnings options,” stated Zackary Irani, CEO of Biomerica.

About Biomerica (NASDAQ: BMRA)
Biomerica, Inc. ( www.biomerica.com ) is a international biomedical technological innovation organization that develops, patents, manufactures and marketplaces superior diagnostic and therapeutic merchandise applied at the position of treatment (in household and in physicians’ workplaces) and in clinic/clinical laboratories for detection and/or treatment method of clinical conditions and ailments. The Company’s goods are made to greatly enhance the wellness and well-staying of individuals, even though decreasing complete health care expenditures. Biomerica’s mainly emphasis is on gastrointestinal and inflammatory diseases where by the Organization has multiple diagnostic and therapeutic merchandise in improvement.

About InFoods®
The Biomerica InFoods® IBS merchandise is intended to allow for doctors to identify affected individual-particular meals (e.g., eggs, broccoli, wheat, potatoes, corn, etc.), that when removed from the diet regime, might ease or improve an individual’s IBS signs or symptoms including, but not minimal to, constipation, diarrhea, bloating, ache and indigestion. This patented, diagnostic-guided therapy is designed to make it possible for for a patient-distinct, guided nutritional regimen to boost IBS results. The level-of-care item is staying produced to permit doctors to perform the check in-place of work employing a finger stick blood sample whilst a clinical lab version of the products is envisioned to be the very first for which the Enterprise will search for regulatory acceptance. A billable CPT code that can be utilised by both of those clinical labs and physicians’ workplaces is previously available for InFoods® diagnostic solutions. Considering that the InFoods® item is a diagnostic-guided therapy, and not a drug, it has no drug type aspect effects. An approximated 45 million people today in The us presently suffer from IBS earning it a top bring about for affected individual medical doctor visits.

The Personal Securities Litigation Reform Act of 1995 supplies a “safe harbor” for forward-searching statements. Selected information included in this push release (as properly as info included in oral statements or other written statements created or to be created by Biomerica) is made up of statements that are ahead-on the lookout, this kind of as statements relating to the efficacy of the Company’s COVID-19 assessments, Food and drug administration clearance, EUA clearance, the rapidity of testing results, uniqueness of a item, precision of products, pricing of the Company’s exam kits, desire for intercontinental orders, availability of the Company’s COVID-19 test kits, and patent security on the exam technological know-how. Such ahead-hunting info includes significant dangers and uncertainties that could considerably have an affect on predicted success in the long term, including, without limitation: effects of studies tests the efficacy of the Company’s COVID-19 tests regulatory approvals required prior to commercialization of the Company’s COVID-19 tests availability of the Company’s COVID-19 take a look at kits capacity, resource and other constraints on our suppliers dependence on our 3rd celebration manufacturers dependence on worldwide transport carriers governmental import/export restrictions demand from customers for our a variety of COVID-19 checks opposition from other related goods and from competition that have noticeably far more money and other means offered to them governmental virus manage laws that make it difficult or impossible for the company to sustain present functions polices and the Company’s skill to acquire patent defense on any aspects of its speedy check technological innovation. Appropriately, this sort of results might differ materially from people expressed in any forward-seeking statements made by or on behalf of Biomerica. Also, opportunity pitfalls and uncertainties include, among other people, fluctuations in the Company’s functioning benefits owing to its organization design and expansion designs, downturns in international and or countrywide economies, the Company’s capacity to increase more capital, the competitive surroundings in which the Corporation will be competing, and the Company’s dependence on strategic associations. The Organization is underneath no obligation to update any ahead-on the lookout statements right after the day of this release.

1. medRxiv preprint doi: https://doi.org/10.1101/2020.03.30.20047365. Accessed 15Jun20

Company Contact:
Firm Spokeperson
949-645-2111